UAMY Stock Climbs As Antimony Contracts And Targets Jump

United States Antimony Corporation stocks have been trading up by 9.33 percent amid heightened demand expectations for critical minerals

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading UAMY

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For UAMY Traders

FY25 revenue at United States Antimony surged 163% to about $39.3M as antimony prices spiked after Chinese export controls, pushing gross profit up 185% to roughly $9.87M.
Heavy growth spending and non‑cash stock compensation left UAMY with a FY25 net loss of $0.04 per share, wider than the prior year’s $0.02 loss.
The company locked in about $354M of multi‑year antimony contracts, raised over $100M of equity, and ended 2025 with $91.3M in cash and investments, while guiding 2026 revenue to $125M.
Mining at Stibnite Hill in Montana restarted earlier than expected, feeding UAMY’s Radersburg plant and Thompson Falls smelter and supporting its domestic antimony growth plans.
H.C. Wainwright and B. Riley both raised price targets on UAMY (to $11.50 and $13) and reiterated Buy ratings after FY25 results, despite a Thompson Falls delay and below‑consensus 2026 guidance.

Live Update At 14:02:51 EDT: On Monday, April 13, 2026 United States Antimony Corporation stock [NYSE: UAMY] is trending up by 9.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

UAMY has turned into a volatility magnet. The stock has been whipping between the low $8s and just over $10 during the recent stretch, with multiple days pushing above $9 before pulling back. That kind of range tells traders there is real momentum and real emotion in this name.

Zooming in on the latest session, UAMY opened near $8.21 and closed at $9.14, grinding higher almost all day. The 5‑minute chart shows a steady staircase from the $8.20s in early trading to the low $9s in the afternoon, with shallow dips being bought. That is classic trend‑day behavior, where short sellers get squeezed and late chasers scramble.

Fundamentals are backing that action. United States Antimony just printed roughly $39.3M in revenue for FY25, up more than 160% year over year, with gross margin around 25%. Yet margins below the operating line are still negative, as UAMY’s EBIT margin sits around -11% and profit margin near -11% as well. The company is clearly in “spend to scale” mode.

More Breaking News

On the balance sheet side, UAMY carries virtually no debt, a current ratio above 5, and a quick ratio around 3.4, plus strong cash. For traders, that means dilution risk is real, but bankruptcy risk is low. The big question is whether this revenue ramp eventually flips those red profit numbers green.

Why Traders Are Locked In On UAMY Now

United States Antimony is finally trading like the critical‑minerals story management has been pitching. FY25 was transformational: revenue jumped 163% to about $39.26M and gross profit climbed 185% to $9.87M, powered by a roughly 230% surge in antimony prices after Chinese export controls tightened supply. UAMY effectively got a macro tailwind at its back and pushed hard on the gas.

That push shows up in the loss line. Earnings per share came in at -$0.04 versus -$0.02 a year earlier and wider than some expected. The company poured cash into growth projects and stock‑based pay, accepting near‑term red ink to build capacity. Traders need to understand this is a high‑beta build‑out, not a tidy dividend story.

The market’s reaction tells the real story. After the revenue print, UAMY stock traded up about 4.6% pre‑market and later finished the day up around 5.4%. Despite the EPS miss, traders focused on the top‑line explosion and the path forward. The company has now secured roughly $354M of multi‑year antimony contracts and ended 2025 with $91.3M in cash and investments versus $18.2M a year earlier. That gives UAMY both revenue visibility and a war chest.

Wall Street noticed. H.C. Wainwright lifted its price target from $10.25 to $11.50, while B. Riley went from $11 to $13, both keeping Buy ratings. This came even as UAMY reiterated 2026 revenue guidance of $125M, below earlier Street expectations near $137.7M, and flagged a delay at its Thompson Falls expansion. Analysts are effectively saying: execution risk is real, but the upside from expanded feedstock, strong policy support for U.S. antimony, and assets like Fostung still outweighs the near‑term hiccups.

Operationally, the story is moving fast. UAMY restarted mining at its Stibnite Hill property in Montana earlier than planned thanks to a mild winter, sending ore back to its Radersburg flotation plant and Thompson Falls smelter. That restart supports the aggressive 2026 targets and adds credibility to management’s push to become a key domestic supplier of antimony — and potentially the first North American tungsten producer in over a decade.

Conclusion

For active traders, UAMY is a classic momentum‑meets‑fundamentals setup. The chart shows strong recent upside, tight intraday stair‑step action, and enough volatility to make both longs and shorts sweat. Underneath that, United States Antimony is scaling hard: revenue nearly tripled, gross profit almost tripled, contracts total about $354M, and cash and investments sit near $91.3M with little debt on the books.

The flip side is just as important. UAMY is still losing money, posting a FY25 loss of $0.04 per share, and relying on heavy capital spending and equity raises to fuel growth. Delays like the one at Thompson Falls remind traders that execution and permitting can hit timelines. Recent filings also show shifting insider and institutional ownership, even if there is no activist pressure yet.

That tension between huge potential and real risk is exactly what short‑term trading feeds on. Key catalysts ahead include ongoing commentary on 2026 guidance, updates on Stibnite Hill and Thompson Falls, any progress on zeolite and tungsten, and the Benchmark conference call, which can move sentiment fast if management leans bullish or cautious. For traders stalking these catalysts, discipline on entries and exits matters as much as the news itself; as Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.”

As Tim Sykes likes to tell students, “The patterns repeat, but the players change — your job is to recognize the setup, manage risk, and never fall in love with the story.” UAMY is giving traders a strong story and a big pattern right now; the challenge is trading the waves without forgetting the risks beneath the surface.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!